These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35222225)

  • 1. The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease:
    Hattori N; Kogo Y; Koebis M; Ishida T; Suzuki I; Tsuboi Y; Nomoto M
    Front Neurol; 2021; 12():752632. PubMed ID: 35222225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
    Tsuboi Y; Koebis M; Kogo Y; Ishida T; Suzuki I; Nomoto M; Hattori N
    J Neurol Sci; 2021 Oct; 429():118070. PubMed ID: 34509801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study.
    Nomoto M; Ishida T; Koebis M; Kamei T; Suzuki I; Hattori N; Tsuboi Y
    J Neurol Sci; 2022 Mar; 434():120083. PubMed ID: 35007919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson's disease: post-hoc analysis of a Japanese phase III study.
    Hattori N; Kamei T; Ishida T; Suzuki I; Nomoto M; Tsuboi Y
    J Neural Transm (Vienna); 2022 Oct; 129(10):1277-1287. PubMed ID: 36001147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson's Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study.
    Bhidayasiri R; Ishida T; Kamei T; Husni RE; Suzuki I; Wu SL; Cho JW
    J Mov Disord; 2023 May; 16(2):180-190. PubMed ID: 37096301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
    Grigoriou S; Martínez-Martín P; Ray Chaudhuri K; Rukavina K; Leta V; Hausbrand D; Falkenburger B; Odin P; Reichmann H
    Brain Behav; 2021 Oct; 11(10):e2336. PubMed ID: 34478245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study.
    Tsuboi Y; Hattori N; Yamamoto A; Sasagawa Y; Nomoto M;
    J Neurol Sci; 2020 Sep; 416():117012. PubMed ID: 32673884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A
    Bhidayasiri R; Koebis M; Kamei T; Ishida T; Suzuki I; Cho JW; Wu SL
    Front Neurol; 2023; 14():1147008. PubMed ID: 37051060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
    Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F
    Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease.
    Kulisevsky J; Martínez-Horta S; Campolongo A; Pascual-Sedano B; Marín-Lahoz J; Bejr-Kasem H; Aracil-Bolaños I; Horta-Barba A; Puig-Davi A; Pagonabarraga J
    Front Neurol; 2022; 13():866502. PubMed ID: 35720066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson's disease population: an open-label, levodopa add-on study.
    ; Bergmans B; Bourgeois P; Cras P; Dethy S; De Klippel N; Franco G; Garraux G; Geens K; Jacquerye P; Jeanjean A; Supiot F; Van der Linden C; Krygier C
    Acta Neurol Belg; 2023 Jun; 123(3):939-947. PubMed ID: 36201116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.
    Cattaneo C; Barone P; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2017; 7(1):95-101. PubMed ID: 27802242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.